BOLT
Price
$3.97
Change
-$0.01 (-0.25%)
Updated
Sep 8 closing price
Capitalization
7.44M
57 days until earnings call
Intraday BUY SELL Signals
VALN
Price
$6.85
Change
-$0.04 (-0.58%)
Updated
Sep 8 closing price
Capitalization
636.51M
64 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BOLT vs VALN

BOLT vs VALN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BOLT vs. VALN commentary
Sep 09, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BOLT is a Hold and VALN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 09, 2026
Stock price -- (BOLT: $3.97 vs. VALN: $6.85)
Brand notoriety: BOLT and VALN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BOLT: 33% vs. VALN: 52%
Market capitalization -- BOLT: $7.44M vs. VALN: $636.51M
BOLT [@Biotechnology] is valued at $7.44M. VALN’s [@Biotechnology] market capitalization is $636.51M. The market cap for tickers in the [@Biotechnology] industry ranges from $134.06B to $0. The average market capitalization across the [@Biotechnology] industry is $2.33B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BOLT’s FA Score shows that 1 FA rating(s) are green whileVALN’s FA Score has 1 green FA rating(s).

  • BOLT’s FA Score: 1 green, 4 red.
  • VALN’s FA Score: 1 green, 4 red.
According to our system of comparison, VALN is a better buy in the long-term than BOLT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BOLT’s TA Score shows that 7 TA indicator(s) are bullish while VALN’s TA Score has 4 bullish TA indicator(s).

  • BOLT’s TA Score: 7 bullish, 3 bearish.
  • VALN’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BOLT is a better buy in the short-term than VALN.

Price Growth

BOLT (@Biotechnology) experienced а -2.46% price change this week, while VALN (@Biotechnology) price change was +4.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.20%. For the same industry, the average monthly price growth was +1.71%, and the average quarterly price growth was +2584.47%.

Reported Earning Dates

BOLT is expected to report earnings on Nov 05, 2026.

VALN is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (-0.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VALN($637M) has a higher market cap than BOLT($7.44M). VALN YTD gains are higher at: -22.336 vs. BOLT (-27.396). BOLT has higher annual earnings (EBITDA): -27.56M vs. VALN (-95.97M). VALN has more cash in the bank: 122M vs. BOLT (17.6M). BOLT has less debt than VALN: BOLT (21.6M) vs VALN (210M). VALN has higher revenues than BOLT: VALN (143M) vs BOLT (4.7M).
BOLTVALNBOLT / VALN
Capitalization7.44M637M1%
EBITDA-27.56M-95.97M29%
Gain YTD-27.396-22.336123%
P/E RatioN/AN/A-
Revenue4.7M143M3%
Total Cash17.6M122M14%
Total Debt21.6M210M10%
TECHNICAL ANALYSIS
Technical Analysis
BOLTVALN
RSI
ODDS (%)
Bullish Trend 5 days ago
89%
Bearish Trend 5 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 5 days ago
86%
Momentum
ODDS (%)
Bullish Trend 5 days ago
83%
Bearish Trend 5 days ago
89%
MACD
ODDS (%)
Bullish Trend 5 days ago
73%
Bearish Trend 5 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 5 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
83%
Bullish Trend 5 days ago
76%
Advances
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 7 days ago
75%
Declines
ODDS (%)
Bearish Trend 7 days ago
89%
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
73%
Bearish Trend 5 days ago
77%
Aroon
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
BOLT
Daily Signal:
Gain/Loss:
VALN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PMPSX165.86N/A
N/A
ProFunds Precious Metals UltraSector Svc
CVCFX18.31N/A
N/A
Victory Pioneer Disciplined Value C
CHRSX23.18N/A
N/A
Invesco Charter S
JACLX18.58N/A
N/A
JHancock Mid Cap Growth C
FMAOX15.37N/A
N/A
Fidelity Advisor Magellan I